
MINIMUM bio
Surry Hills, Australiaminimumbio.comFrom their website, Nov 2026
Work here? Claim this listing
About
MINIMUM bio develops a molecular glue drug discovery platform that identifies protein targets for bioactive compounds and builds rapalog libraries for new drug discovery. It works with small molecules, biologics, and molecular glues in oncology, immunology, and longevity. The company has labs in Austin, Texas, and Sydney, Australia.
Services
Proteome-wide drug target discovery
Identifies binding partners for a bioactive compound across the human proteome without a prior target hypothesis.
Mechanism-of-action deconvolution
Resolves the targets of phenotypically active compounds to clarify how they work.
Drug repositioning support
Uses target discovery to help identify new uses for existing compounds.
Off-target identification
Finds binding partners beyond the intended target for a compound.
Molecular glue discovery
Screens compounds against proteome-wide libraries to identify FKBP-recruiting molecular glue targets.
Rapalog library co-development
Develops FKBP12-recruiting rapamycin analog libraries with partners.
- Turnaround
- 1-2 weeks
Capabilities
- Assays and studies
- Small molecules
- Phage biopanning
- Target identification
- Iterative screening
- Next-generation sequencing readout
- Scale and capacity
- Thousands to millions of rapamycin analogs
- Therapeutic areas
- Oncology
- Immunology
- Longevity
Instruments and platforms
- Next-generation sequencing
Modalities and species
- Modalities
- Small molecule
- mRNA
- Gene editing
- Species and models
- Human proteome
- T7 phage
- Phage-displayed cDNA libraries
Details
- Team
- 50% female, 80% PhDs
- Office
- 1601 Elm Street Dallas TX 75201 USA
- Sites
- Dallas, USA · Austin, USA · Sydney, Australia